



2 valuable tools

for your GI distress diagnostic workup

IBSDetex™ Test and Celiac Disease Testing



Is it **IBS**, and is it treatable? This test helps you know.

The IBSDetex test is for **post-infectious IBS-D and IBS-M**

Irritable bowel syndrome (IBS) has traditionally been a diagnosis of exclusion. Now there is a tool to include in your IBS diagnostic workup: IBSDetex from Quest Diagnostics.

IBSDetex provides physicians and their patients with a quick, simple, first-line diagnostic test for post-infectious IBS-D (diarrhea-predominant IBS) and IBS-M (IBS with both diarrhea and constipation).

A simple blood test to include in your IBS diagnostic workup

- Confirms post-infectious IBS-D and IBS-M with 89% positive predictive value¹
- 90% specificity¹
- Can identify patients with IBS-D associated with intestinal bacterial overgrowth
- May avoid the unnecessary use of healthcare resources²
- Increases confidence in your diagnosis of IBS
- From the world's leading provider of diagnostic testing, information, and services

From test to treatable

IBSDetex is designed to identify those patients who present with symptoms of IBS-D and IBS-M associated with a prior episode of gastroenteritis. This group of patients may be candidates for treatment of their IBS.



More than 40% of patients with diarrhea-predominant IBS (IBS-D) have suffered a previous episode of gastroenteritis¹

IBSDetex. When the result is clear, you can be, too.

Identify and manage **celiac disease** with greater certainty

Get highly accurate serologic and genetic testing for celiac disease from a single source

Celiac disease is an intestinal immune reaction triggered by eating gluten. Diagnosis can be clinically challenging, because many patients can be asymptomatic and many symptoms are nonspecific to celiac disease.

Quest Diagnostics gives you the testing solutions you need to aid in the diagnosis and management of this challenging disease, all from one convenient source.

What tests are available for celiac disease?

- Tissue transglutaminase antibodies (IgA tTG) test: 93-96% sensitivity and 99-100% specificity³
- Other antibody tests, including antigliadin IgG, antigliadin IgA, and EMA
- Genetic testing: human leukocyte antigen (HLA) alleles DQ2 and DQ8—a negative test for both rules out celiac disease with 99% confidence^{4,5}
- Testing for nutritional deficiencies in newly diagnosed patients
- Additional follow-up testing 6 months after diagnosis and annually thereafter

Important facts about celiac disease

Precipitated by **gliadin**, a component of gluten protein

Improves with **gluten withdrawal** (e.g., gluten-free diet)

Affects approximately **1 in 133 Americans**⁶

.....

~83% of patients with celiac disease go undiagnosed⁶

.....

From immediate diagnosis to long-term care, Quest Diagnostics is your single source for celiac disease testing.

Trust Quest Diagnostics for all of your GI test ordering.
 From the newest diagnostic tools to routine follow-up, we have the tests you need in order to do the very best for your patients.

Test Name	Test Code	CPT Code*
Irritable Bowel Syndrome		
IBSDetex	94445	83520 (x2)
Celiac Disease		
Gliadin (Deamidated Peptide) Antibody (IgG, IgA)	8889	83516 (x2)
Gliadin (Deamidated Peptide) Antibody (IgA)	11228	83516
Gliadin (Deamidated Peptide) Antibody (IgG)	11212(X)	83516
HLA Typing for Celiac Disease		
Includes HLA-DQ2 (DQA1*05/DQB1*02), HLA-DQ8 (DQA1*03/DQB1*0302), HLA-DQA1*, HLA-DQB1*	17135(X)	81376, 81382
Celiac Disease Comprehensive Panel**		
Includes Tissue Transglutaminase, IgA with Reflexes; Total IgA with Reflex	19955	82784, 83516
Celiac Disease Comprehensive Panel, Infant**		
Includes Tissue Transglutaminase IgA with Reflexes, Gliadin (Deamidated) Antibody IgA, and Total IgA, Serum with Reflex	15981	83516 (x2), 82784
Celiac Disease Panel 2 with Reflex to Endomysial Antibody Titer***		
Includes Gliadin (Deamidated) Antibody (IgG, IgA); Tissue Transglutaminase Antibody (IgG, IgA); Endomysial Antibody Screen (IgA); IgA, Serum. If the Endomysial Antibody Screen IgA is abnormal, Endomysial Antibody Titer is performed at an additional charge (CPT code(s): 86256).	58319	82784, 83516 (x4), 86255

* The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

** If the Total IgA is less than the lower limit of the reference range, based on age, Tissue Transglutaminase IgG will be performed at an additional charge (CPT code(s): 83516).

*** Panel components may be ordered individually.



For more information, visit QuestDiagnostics.com/CD or QuestDiagnostics.com/IBS.

References

1. Pimentel M, Morales W, Rezaie A, et al. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. *PLOS ONE*. 2015;10:e0126438.
2. Pimentel M, Purdy C, Magar R, Rezaie A. A predictive model to estimate cost savings of a novel diagnostic blood panel for diagnosis of diarrhea-predominant irritable bowel syndrome. *Clin Ther*. 2016;38:1638–52.
3. Abdulkarim AS, Murray JA. Review article: The diagnosis of coeliac disease. *Aliment Pharm Ther*. 2003;17:987–95.
4. Schuppan D. Current concepts of celiac disease pathogenesis. *Gastroenterology*. 2000;119:234–42.
5. Kaukinen K, et al. HLA-DQ typing in the diagnosis of celiac disease. *Am J Gastroenterol*. 2002;97:695–9.
6. Celiac disease facts and figures. National Foundation for Celiac Awareness. Available at www.celiaccentral.org/ceeliac-disease/facts-and-figures. Accessed February 13, 2017.

QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners.

© 2017 Quest Diagnostics Incorporated. All rights reserved. SB6707 3/2017

